Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Quick Facts
Nilo Therapeutics: Series A Funding Round
Nilo Therapeutics has successfully raised $101M in Series A funding, reaching a valuation of $450M.
Company Overview
Developing therapies based on neuro-immunology research
Funding Details
The Series A round was led by Boxer Capital, with participation from Perceptive Advisors.
Company Information
- Headquarters: New York, NY
- Founded: 2023
- Employees: 60+
- Category: Biotech
Investment
Nilo Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Boxer Capital: Verified investor in Series A
- Perceptive Advisors: Verified investor in Series A
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Expedition Therapeutics raises $165M Series A at $700M valuation
Expedition Therapeutics raises $165M in Series A at $700M valuation. Developer of therapies for inflammatory and respiratory diseases...